8 active not recruiting, 5 recruiting, 3 completed, 1 terminated. 10 Phase 1, 8 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 4, Recruiting 4, Completed 2 |
| Phase 2 | 8 | Active not recruiting 5, Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Cetrelimab: new trials by email Literature Review of Cetrelimab trials Research Report on Cetrelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-1761981 in Participants With Solid Tumors JNJ-1761981, Cetrelimab - Neoplasms | Phase 1 | Recruiting | Johnson & Johnson Enterprise Innovation Inc. | 66 | 2026-05-18 | 2026-09-25 |
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer tolododekin alfa, Cetrelimab - Non Small Cell Lung Cancer | Phase 1 | Recruiting | Ankyra Therapeutics, Inc | 60 | 2025-10-22 | 2026-09-02 |
| CD8 PET Imaging in Metastatic Solid Tumours 89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab - Locally Advanced Solid Tumor | Phase 2 | Recruiting | University Medical Center Groningen | 30 | 2025-03-11 | 2026-02-09 |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1 - Neoplasms | Phase 1 | Recruiting | Johnson & Johnson Enterprise Innovation Inc. | 126 | 2024-04-10 | 2026-09-25 |
| A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer JNJ-86974680, Cetrelimab, Radiation Therapy - Carcinoma, Non-small-Cell Lung | Phase 1 | Active not recruiting | Johnson & Johnson Enterprise Innovation Inc. | 67 | 2023-11-27 | 2026-09-25 |
| A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer Cetrelimab, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 71 | 2023-05-18 | 2026-09-25 |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer Pasritamig, Cetrelimab, Cabazitaxel - Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer | Phase 1 | Recruiting | Janssen Research & Development, LLC | 300 | 2023-04-26 | 2026-09-25 |
| A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) TAR-200, Cetrelimab, BCG Vesiculture - Bladder Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 1135 | 2023-03-23 | 2026-09-25 |
| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder TAR-200, Cetrelimab - Urinary Bladder Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 163 | 2022-07-07 | 2026-06-23 |
| A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection Cetrelimab, Placebo - Hepatitis B, Chronic | Phase 1 | Completed | Janssen Research & Development, LLC | 11 | 2022-04-19 | 2023-07-24 |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy TAR-200, Cetrelimab - Urinary Bladder Neoplasms | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 220 | 2020-12-18 | 2026-09-25 |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Cetrelimab, TAR-200, Cisplatin - Urinary Bladder Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 518 | 2020-12-07 | 2026-09-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers JNJ-63723283, Erdafitinib - Neoplasm | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 22 | 2018-08-31 | 2025-04-28 |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer Erdafitinib, Cetrelimab, Cisplatin - Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 125 | 2018-04-05 | 2026-08-28 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers JNJ-63723283 - Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 234 | 2016-11-21 | 2026-08-31 |
Neoplasms (4) · Urinary Bladder Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Prostatic Neoplasms (2) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Small Cell (1) · Carcinoma, Transitional Cell (1) · Hepatitis B, Chronic (1) · Small Cell Lung Carcinoma (1)
Janssen Research & Development, LLC (9) · Johnson & Johnson Enterprise Innovation Inc. (3) · Ankyra Therapeutics, Inc (1) · Janssen Pharmaceutical K.K. (1) · M.D. Anderson Cancer Center (1) · Rahul Aggarwal (1) · University Medical Center Groningen (1)
United States (14) · Spain (12) · France (7) · South Korea (7) · United Kingdom (7) · Belgium (6) · Germany (6) · Italy (6) · Poland (6) · Australia (4) · Brazil (4) · Canada (4) · Japan (4) · Netherlands (4) · Russia (4)
Ana Aparicio (1) · Elisabeth G.E. de Vries, MD, PhD (1) · Rahul Aggarwal, MD (1)
PMID 35298698, PMID 39971605, PMID 40737582, PMID 40885199, PMID 41337691, PMID 41538748, PMID 42313189
2023 (7), 2016 (1), 2017 (1)